Immunogenicity and safety of a multi-dose quadrivalent inactivated influenza vaccine in individuals aged 6 months to 17 years: a randomized phase III trial

[tetano]

Hum Vaccin Immunother. 2019 Dec 6. doi: 10.1080/21645515.2019.1697595. [Epub ahead of print] Immunogenicity and safety of a multi-dose quadrivalent inactivated influenza vaccine in individuals aged 6 months to 17 years: a randomized phase III trial.

Ojeda J¹, Arredondo JL², Salcedo P³, Paredes-Paredes M⁴, Dupuy M⁵, Petit C⁶, Chabanon AL⁷, Rivas E⁸, Gurunathan S⁹, De Bruijn I¹⁰, Pepin S¹¹.
Author information

1 Global Clinical Science, Sanofi Pasteur, Colonia Coyoac?n, Mexico City, Mexico. Email: joyce.ojeda@sanofi.com. 2 Instituto Nacional de Pediatr?a, Unidad de Investigaci?n Cl?nica, Colonia Insurgentes Cuicuilco, Coyoac?n, Mexico City, Mexico. Email: arredondo.joseluis@gmail.com. 3 Hospital General de Ecatepec "Las Am?ricas", Fraccionamiento las Am?ricas, Ecatepec de Morelos, Estado de M?xico, Mexico. Email: salcedolozadaperla@gmail.com. 4 JM Research Clinical Research Center, Cuernavaca, Morelos, Mexico. Email: mercedes@jmresearch.org. 5 Global Biostatistical Sciences, Sanofi Pasteur, Marcy l'?toile, France. Email: martin.dupuy@sanofi.com. 6 Global Clinical Immunology, Sanofi Pasteur, Marcy l'?toile, France. Email: celine.petit@sanofi.com. 7 Global Pharmacovigilance, Sanofi Pasteur, Campus Sanofi Lyon, Lyon, France. Email: anne-laure.chabanon@sanofi.com. 8 Global Clinical Sciences, Sanofi Pasteur, Colonia Coyoac?n, Mexico City, Mexico. Email: enrique.rivas@sanofi.com. 9 Global Clinical Sciences, Sanofi Pasteur, Swiftwater, PA, US. Email: sanjay.gurunathan@sanofi.com. 10 Global Clinical Sciences, Sanofi Pasteur, Marcy l'?toile, France. Email: iris.debruijn@sanofi.com. 11 Global Clinical Sciences, Sanofi Pasteur, Marcy l'?toile, France. Email: stephanie.pepin@sanofi.com.

Abstract

Annual vaccination is the most effective way to prevent seasonal influenza. Influenza vaccines in multi-dose vial (MDV) formats can facilitate timely vaccination of large populations by reducing per-dose costs and cold storage requirements compared to single-dose pre-filled syringe (PFS) formats. MDV vaccines require thiomersal or another preservative to prevent microbial contamination. We conducted a randomized, open-label trial in 302 healthy subjects aged 6 months to 17 years to evaluate the immunogenicity and safety of a quadrivalent influenza vaccine (QIV) in a thiomersal-containing MDV format compared to the licensed thiomersal-free PFS format. Subjects were randomly assigned in a 1:1 ratio to receive the MDV (n=153) or PFS (n=149) format. Post-vaccination hemagglutination inhibition titers for all four vaccine strains were ≥4.9-fold higher than baseline titers with no difference in magnitude between the MDV and PFS groups. Seroconversion rates per strain were also comparable between the two groups. There were no differences in reactogenicity or safety between the two vaccine formats. These results showed that the MDV format of QIV was as safe and immunogenic as the PFS format in infants, children, and adolescents. These findings support the use of MDV QIV as a resource-saving alternative for seasonal influenza vaccination.


KEYWORDS:

Quadrivalent influenza vaccines; adolescents; children; immunogenicity; influenza; safety; vaccination

PMID: 31810418 DOI: 10.1080/21645515.2019.1697595